{"url_path":"/sec/cprx/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001369568-26-000002-index.html","accession_number":"0001369568-26-000002","cik":"0001369568","ticker":"CPRX","issuer_name":"CATALYST PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1369568/0001369568-26-000002-index.html","primary_entity_key":"0001369568","primary_entity_name":"CATALYST PHARMACEUTICALS, INC."},"word_count":437,"has_tables":true,"body_markdown":"10-Q\n\nfalse--12-31Q10001369568355http://catalystpharma.com/20260331#PresidentAndChiefExecutiveOfficerMember6 yearshttp://fasb.org/us-gaap/2025#LiabilitiesCurrenthttp://fasb.org/us-gaap/2025#LiabilitiesCurrent00013695682022-07-1100013695682025-12-310001369568cprx:U.s.RightsForFycompaMembersrt:MinimumMembercprx:RoyaltyMoreThanHundredAndTwentyFiveMillionMember2026-01-012026-03-310001369568us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001369568us-gaap:FurnitureAndFixturesMember2025-12-310001369568srt:MaximumMemberus-gaap:ComputerEquipmentMember2026-03-310001369568cprx:U.s.RightsForFycompaMember2023-01-242023-01-240001369568us-gaap:SalesRevenueNetMembercprx:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-03-3100013695682025-03-310001369568us-gaap:CommonStockMember2025-01-012025-03-310001369568cprx:LicenseAgreementForRuzurgiMember2026-01-012026-03-310001369568srt:MinimumMembercprx:AgamreeMembercprx:RoyaltyMoreThanTwoBillionMember2026-01-012026-03-310001369568cprx:U.s.RightsForFycompaMembercprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember2026-01-012026-03-310001369568us-gaap:CollaborativeArrangementMembercprx:DydoPharmaIncMember2026-01-012026-03-310001369568cprx:AgamreeMember2026-03-310001369568cprx:RoyaltyForAdditionalIndicationsAndMilestonesOfUpToFiftyMillionMoreMembercprx:AgamreeMember2025-01-012025-09-300001369568cprx:SharePurchaseProgramMember2025-10-012025-10-310001369568us-gaap:CommonStockMember2025-03-310001369568cprx:AgamreeMembercprx:RoyaltyMoreThanTwoBillionMember2026-01-012026-03-310001369568us-gaap:RetainedEarningsMember2024-12-310001369568us-gaap:USTreasurySecuritiesMember2026-03-310001369568us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001369568cprx:CalendarYears2022Through2025Membercprx:LicenseAndAssetPurchaseAgreementMember2022-07-112022-07-1100013695682023-07-012023-07-310001369568srt:MinimumMembercprx:RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMembercprx:AgamreeMember2026-01-012026-03-3100013695682025-01-012025-03-310001369568us-gaap:FairValueInputsLevel1Member2026-03-310001369568cprx:LicenseAgreementWithBioMarinMember2026-01-012026-03-310001369568us-gaap:FairValueInputsLevel1Member2025-12-310001369568us-gaap:RetainedEarningsMember2025-01-012025-03-310001369568cprx:RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMembersrt:MinimumMembercprx:AgamreeMember2026-01-012026-03-310001369568us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001369568cprx:LicenseAndAcquiredIntangiblesForFycompaMember2026-01-012026-03-310001369568us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001369568cprx:FycompaMember2026-01-012026-03-310001369568cprx:LicenseAgreementForRuzurgiMember2022-07-112022-07-110001369568cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember2026-01-012026-03-310001369568us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2026-03-310001369568us-gaap:SoftwareDevelopmentMember2026-03-3100013695682023-07-110001369568cprx:AgamreeMember2025-01-012025-12-310001369568us-gaap:LeaseholdImprovementsMembersrt:MinimumMember2026-03-310001369568cprx:RoyaltyLessThanHundredMillionMembercprx:AgamreeMembersrt:MaximumMember2026-01-012026-03-310001369568us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2026-03-310001369568cprx:RoyaltyForSantheraSalesBasedMilestonesMembercprx:AgamreeMember2026-01-012026-03-310001369568cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMembercprx:U.s.RightsForFycompaMembersrt:MinimumMember2026-01-012026-03-310001369568cprx:OptionsToPurchaseCommonStockMember2026-01-012026-03-310001369568cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMembercprx:U.s.RightsForFycompaMembersrt:MaximumMember2026-01-012026-03-310001369568cprx:RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMembercprx:AgamreeMember2026-01-012026-03-3100013695682024-07-110001369568us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-01-012025-03-310001369568us-gaap:RetainedEarningsMember2026-01-012026-03-310001369568cprx:FycompaMember2025-01-012025-03-310001369568cprx:U.s.RightsForFycompaMember2026-03-310001369568srt:MinimumMembercprx:U.s.RightsForFycompaMembercprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember2026-01-012026-03-310001369568cprx:RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMembercprx:AgamreeMember2026-01-012026-03-310001369568srt:MinimumMember2026-01-012026-03-310001369568cprx:TwoThousandTwentyThreeShelfRegistrationStatementMember2023-09-080001369568cprx:MergerAgreementWithAngeliniPharmaSPAMemberus-gaap:SubsequentEventMember2026-05-060001369568cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember2026-03-310001369568cprx:LicenseAndOtherRevenueMember2025-01-012025-03-310001369568us-gaap:CommonStockMember2025-12-310001369568cprx:PublicOfferingMember2024-01-092024-01-090001369568srt:MinimumMembercprx:RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMembercprx:AgamreeMember2026-01-012026-03-310001369568srt:MaximumMember2026-01-012026-03-310001369568us-gaap:LeaseholdImprovementsMember2026-03-310001369568cprx:LicenseAgreementForRuzurgiMember2023-07-112023-07-110001369568cprx:RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMembercprx:AgamreeMembersrt:MaximumMember2026-01-012026-03-310001369568us-gaap:MoneyMarketFundsMember2025-12-310001369568srt:MinimumMembercprx:AgamreeMembercprx:RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember2026-01-012026-03-310001369568cprx:RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMembercprx:AgamreeMember2026-01-012026-03-3100013695682025-01-012025-09-300001369568us-gaap:SellingGeneralAndAdministrativeExpensesMember2026-01-012026-03-310001369568cprx:RoyaltyLessThanHundredMillionMembercprx:AgamreeMember2026-01-012026-03-310001369568us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001369568us-gaap:FurnitureAndFixturesMember2026-03-310001369568cprx:RoyaltyLessThanTwoHundredFiftyMillionMembercprx:AgamreeMember2026-01-012026-03-310001369568us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2025-12-310001369568us-gaap:CommonStockMembercprx:TwoThousandEighteenStockIncentivePlanMember2026-03-310001369568cprx:LicensedAndAcquiredIntangiblesForAgamreeMember2025-12-310001369568cprx:U.s.RightsForFycompaMembercprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMembersrt:MaximumMember2026-01-012026-03-310001369568cprx:AgamreeMember2026-01-012026-03-310001369568srt:MinimumMembercprx:AgamreeMembercprx:RoyaltyMoreThanThreeHundredMillionMember2026-01-012026-03-310001369568cprx:FirdapseMember2026-01-012026-03-310001369568us-gaap:RestrictedStockUnitsRSUMember2026-03-310001369568us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001369568cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember2025-01-012025-03-310001369568cprx:RoyaltyForSantheraSalesBasedMilestonesMembercprx:AgamreeMember2025-10-012025-12-310001369568us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001369568us-gaap:CommonStockMember2026-01-012026-03-3100013695682026-01-012026-03-310001369568cprx:SettlementAgreementMember2026-05-072026-05-070001369568cprx:LicenseAgreementForRuzurgiMembersrt:MaximumMember2026-01-012026-03-310001369568us-gaap:CommonStockMember2024-12-310001369568cprx:LicenseAgreementForRuzurgiMember2025-07-112025-07-110001369568us-gaap:SalesRevenueNetMembercprx:CustomerAMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-03-310001369568us-gaap:RestrictedStockMember2026-01-012026-03-310001369568cprx:UsTreasuryBondSecuritiesCashEquivalentsMember2025-01-012025-12-310001369568us-gaap:AdditionalPaidInCapitalMember2024-12-3100013695682025-01-012025-12-310001369568cprx:U.s.RightsForFycompaMembercprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionOneMember2026-01-012026-03-310001369568srt:MinimumMembercprx:LicenseAgreementForRuzurgiMember2026-01-012026-03-310001369568cprx:RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMembercprx:AgamreeMembersrt:MaximumMember2026-01-012026-03-310001369568cprx:U.s.RightsForFycompaMember2023-01-012023-01-310001369568cprx:RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMembersrt:MinimumMembercprx:AgamreeMember2026-01-012026-03-310001369568cprx:LicenseAndAcquiredIntangiblesForFycompaMember2025-01-012025-03-310001369568cprx:LicenseAndAssetPurchaseAgreementMember2022-07-112022-07-110001369568cprx:LicensedAndAcquiredIntangiblesForAgamreeMember2026-01-012026-03-310001369568us-gaap:LeaseholdImprovementsMembersrt:MaximumMember2026-03-310001369568cprx:U.s.RightsForFycompaMembercprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMembersrt:MaximumMember2025-01-012025-09-300001369568cprx:U.s.RightsForFycompaMembercprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMemberus-gaap:RoyaltyAgreementTermsMember2026-01-012026-03-310001369568cprx:AgamreeMembercprx:RoyaltyMoreThanThreeHundredMillionMember2026-01-012026-03-310001369568cprx:ProductRevenueNetMember2025-01-012025-03-310001369568cprx:LicensedAndAcquiredIntangiblesForAgamreeMember2025-01-012025-03-310001369568cprx:RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMembercprx:AgamreeMember2026-01-012026-03-310001369568cprx:AgamreeMember2023-07-190001369568us-gaap:SoftwareDevelopmentMember2025-12-310001369568us-gaap:AdditionalPaidInCapitalMember2025-12-310001369568us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-03-310001369568cprx:RoyaltyMoreThanOneBillionAndLessThanTwoBillionMembercprx:AgamreeMembersrt:MaximumMember2026-01-012026-03-310001369568us-gaap:RetainedEarningsMember2025-12-310001369568us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2026-03-310001369568us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001369568cprx:LicenseAndOtherRevenueMember2026-01-012026-03-3100013695682026-03-310001369568cprx:AgamreeMember2026-01-012026-03-310001369568cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMembercprx:U.s.RightsForFycompaMember2026-01-012026-03-310001369568cprx:UsTreasuryBondSecuritiesCashEquivalentsMember2026-01-012026-03-310001369568cprx:AgamreeMember2023-10-260001369568us-gaap:CommonStockMembercprx:SharePurchaseProgramMember2025-10-310001369568cprx:RoyaltyMoreThanOneBillionAndLessThanTwoBillionMembercprx:AgamreeMember2026-01-012026-03-310001369568srt:MinimumMembercprx:LicenseAgreementWithBioMarinMember2026-01-012026-03-310001369568cprx:RoyaltyMoreThanOneBillionAndLessThanTwoBillionMembersrt:MinimumMembercprx:AgamreeMember2026-01-012026-03-310001369568cprx:LicenseAndAcquiredIntangiblesForFycompaMember2025-12-310001369568cprx:OptionsToPurchaseCommonStockMember2026-03-310001369568cprx:AgamreeMembersrt:MaximumMembercprx:RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember2026-01-012026-03-310001369568cprx:TwoThousandTwentyThreeShelfRegistrationStatementMember2024-01-092024-01-090001369568cprx:LicenseAgreementWithBioMarinMember2012-10-262012-10-260001369568us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001369568srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2026-03-310001369568us-gaap:CollaborativeArrangementMembercprx:DydoPharmaIncMember2025-01-012025-03-310001369568cprx:UsTreasuryBondSecuritiesCashEquivalentsMember2026-03-310001369568cprx:AgamreeMember2023-10-012023-12-310001369568cprx:AgamreeMember2023-07-012023-07-310001369568us-gaap:CommonStockMember2026-03-310001369568cprx:FirdapseMember2025-01-012025-03-3100013695682026-05-070001369568us-gaap:LeaseholdImprovementsMember2025-12-3100013695682024-12-310001369568cprx:MergerAgreementWithAngeliniPharmaSPAMemberus-gaap:SubsequentEventMember2026-05-062026-05-060001369568us-gaap:SalesRevenueNetMembercprx:CustomersMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-03-310001369568us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001369568cprx:RoyaltyMoreSevenHundredAndFiftyMillionAndLessThanOneBillionMembercprx:AgamreeMembersrt:MaximumMember2026-01-012026-03-310001369568cprx:RoyaltyLessThanTwoHundredFiftyMillionMembercprx:AgamreeMembersrt:MaximumMember2026-01-012026-03-310001369568srt:MinimumMemberus-gaap:ComputerEquipmentMember2026-03-310001369568cprx:LicensedAndAcquiredIntangiblesForAgamreeMember2026-03-310001369568us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001369568cprx:LicenseAndAcquiredIntangiblesForFycompaMember2026-03-310001369568cprx:UsTreasuryBondSecuritiesCashEquivalentsMember2025-12-310001369568us-gaap:CommonStockMembercprx:SharePurchaseProgramMember2025-01-012025-03-310001369568cprx:U.s.RightsForFycompaMembercprx:RoyaltyMoreThanHundredAndTwentyFiveMillionMember2026-01-012026-03-310001369568us-gaap:RetainedEarningsMember2025-03-310001369568us-gaap:SalesRevenueNetMembercprx:CustomersMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-03-310001369568us-gaap:MoneyMarketFundsMember2026-03-310001369568cprx:LicenseAgreementForRuzurgiMember2022-07-112025-12-310001369568cprx:OptionsToPurchaseCommonStockMember2025-01-012025-03-310001369568cprx:LicenseAndAcquiredIntangiblesForRUZURGIMember2025-12-310001369568cprx:AgamreeMember2025-01-012025-03-310001369568cprx:ProductRevenueNetMember2026-01-012026-03-310001369568cprx:U.s.RightsForFycompaMemberus-gaap:RoyaltyAgreementTermsMembercprx:RoyaltyMoreThanHundredAndTwentyFiveMillionMember2026-01-012026-03-310001369568cprx:CalendarYear2026Membercprx:LicenseAndAssetPurchaseAgreementMember2022-07-112022-07-110001369568cprx:LicenseAgreementWithBioMarinMembersrt:MaximumMember2026-01-012026-03-310001369568us-gaap:AdditionalPaidInCapitalMember2026-03-310001369568cprx:RoyaltyMoreTwoHundredAndFiftyMillionAndLessThanFiveHundredMillionMembercprx:AgamreeMembersrt:MaximumMember2026-01-012026-03-310001369568cprx:U.s.RightsForFycompaMember2023-01-012023-09-300001369568us-gaap:RetainedEarningsMember2026-03-310001369568cprx:LicenseAgreementForRuzurgiMember2024-07-112024-07-110001369568us-gaap:AdditionalPaidInCapitalMember2025-03-310001369568cprx:AgamreeMembercprx:RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember2026-01-012026-03-310001369568cprx:RoyaltyForAdditionalIndicationsAndMilestonesMembercprx:AgamreeMember2026-03-31xbrli:pureutr:sqftcprx:Segmentxbrli:sharescprx:Voteiso4217:USDiso4217:USDxbrli:sharesiso4217:CHFxbrli:shares\n\n[Table of Contents](#toc_page)\n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nFORM 10-Q\n\n[Mark One]\n\n☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the Quarterly Period Ended March 31, 2026\n\nOR\n\n☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nCommission File No. 001-33057\n\nCATALYST PHARMACEUTICALS, INC.\n\n(Exact name of registrant as specified in its charter)\n\nDelaware\n\n76-0837053\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n(IRS Employer\n\nIdentification No.)\n\n355 Alhambra Circle\n\nSuite 801\n\nCoral Gables, Florida\n\n33134\n\n(Address of principal executive offices)\n\n(Zip Code)\n\nRegistrant’s telephone number, including area code: (305) 420-3200\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of Each Class\n\n \n\nTicker\n\nSymbol\n\n \n\nName of Exchange\n\non Which Registered\n\nCommon Stock, par value $0.001 per share\n\n \n\nCPRX\n\n \n\nNASDAQ Capital Market\n\nIndicate by checkmark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such report(s), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:\n\nLarge accelerated filer\n\n☒\n\nAccelerated Filer\n\n☐\n\nNon-accelerated filer\n\n☐\n\nSmaller reporting company\n\n☐\n\nEmerging growth company\n\n☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\nIndicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date 122,380,992 shares of common stock, $0.001 par value per share, were outstanding as of May 7, 2026.\n\n \n\n \n\n[Table of Contents](#toc_page)\n\n \n\nCATALYST PHARMACEUTICALS, INC.\n\nINDEX\n\nPART I. FINANCIAL INFORMATION"}